Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients
<p dir="ltr">The COVID-19 pandemic has negatively impacted the global public health and the international economy; therefore, there is an urgent need for an effective therapy to treat COVID-19 patients. Mesenchymal stem cells (MSCs) have been proposed as an emerging therapeutic optio...
محفوظ في:
| المؤلف الرئيسي: | |
|---|---|
| مؤلفون آخرون: | |
| منشور في: |
2020
|
| الموضوعات: | |
| الوسوم: |
إضافة وسم
لا توجد وسوم, كن أول من يضع وسما على هذه التسجيلة!
|
| _version_ | 1864513511199080448 |
|---|---|
| author | Sara Al-Khawaga (4792761) |
| author2 | Essam M. Abdelalim (5768072) |
| author2_role | author |
| author_facet | Sara Al-Khawaga (4792761) Essam M. Abdelalim (5768072) |
| author_role | author |
| dc.creator.none.fl_str_mv | Sara Al-Khawaga (4792761) Essam M. Abdelalim (5768072) |
| dc.date.none.fl_str_mv | 2020-10-15T12:00:00Z |
| dc.identifier.none.fl_str_mv | 10.1186/s13287-020-01963-6 |
| dc.relation.none.fl_str_mv | https://figshare.com/articles/journal_contribution/Potential_application_of_mesenchymal_stem_cells_and_their_exosomes_in_lung_injury_an_emerging_therapeutic_option_for_COVID-19_patients/26299555 |
| dc.rights.none.fl_str_mv | CC BY 4.0 info:eu-repo/semantics/openAccess |
| dc.subject.none.fl_str_mv | Biomedical and clinical sciences Cardiovascular medicine and haematology Medical biotechnology Stem cells MSCs SARS-CoV-2 ARDS Exosome Treatment Clinical trials Pneumonia |
| dc.title.none.fl_str_mv | Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients |
| dc.type.none.fl_str_mv | Text Journal contribution info:eu-repo/semantics/publishedVersion text contribution to journal |
| description | <p dir="ltr">The COVID-19 pandemic has negatively impacted the global public health and the international economy; therefore, there is an urgent need for an effective therapy to treat COVID-19 patients. Mesenchymal stem cells (MSCs) have been proposed as an emerging therapeutic option for the SARS-CoV-2 infection. Recently, numerous clinical trials have been registered to examine the safety and efficacy of different types of MSCs and their exosomes for treating COVID-19 patients, with less published data on the mechanism of action. Although there is no approved effective therapy for COVID-19 as of yet, MSC therapies showed an improvement in the treatment of some COVID-19 patients. MSC’s therapeutic effect is displayed in their ability to reduce the cytokine storm, enhance alveolar fluid clearance, and promote epithelial and endothelial recovery; however, the safest and most effective route of MSC delivery remains unclear. The use of poorly characterized MSC products remains one of the most significant drawbacks of MSC-based therapy, which could theoretically promote the risk for thromboembolism. Optimizing the clinical-grade production of MSCs and establishing a consensus on registered clinical trials based on cell-product characterization and mode of delivery would aid in laying the foundation for a safe and effective therapy in COVID-19. In this review, we shed light on the mechanistic view of MSC therapeutic role based on preclinical and clinical studies on acute lung injury and ARDS; therefore, offering a unique correlation and applicability in COVID-19 patients. We further highlight the challenges and opportunities in the use of MSC-based therapy.</p><h2>Other Information</h2><p dir="ltr">Published in: Stem Cell Research & Therapy<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1186/s13287-020-01963-6" target="_blank">https://dx.doi.org/10.1186/s13287-020-01963-6</a></p> |
| eu_rights_str_mv | openAccess |
| id | Manara2_d97900f26763c90dcc5aa9bd61ae674e |
| identifier_str_mv | 10.1186/s13287-020-01963-6 |
| network_acronym_str | Manara2 |
| network_name_str | Manara2 |
| oai_identifier_str | oai:figshare.com:article/26299555 |
| publishDate | 2020 |
| repository.mail.fl_str_mv | |
| repository.name.fl_str_mv | |
| repository_id_str | |
| rights_invalid_str_mv | CC BY 4.0 |
| spelling | Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patientsSara Al-Khawaga (4792761)Essam M. Abdelalim (5768072)Biomedical and clinical sciencesCardiovascular medicine and haematologyMedical biotechnologyStem cellsMSCsSARS-CoV-2ARDSExosomeTreatmentClinical trialsPneumonia<p dir="ltr">The COVID-19 pandemic has negatively impacted the global public health and the international economy; therefore, there is an urgent need for an effective therapy to treat COVID-19 patients. Mesenchymal stem cells (MSCs) have been proposed as an emerging therapeutic option for the SARS-CoV-2 infection. Recently, numerous clinical trials have been registered to examine the safety and efficacy of different types of MSCs and their exosomes for treating COVID-19 patients, with less published data on the mechanism of action. Although there is no approved effective therapy for COVID-19 as of yet, MSC therapies showed an improvement in the treatment of some COVID-19 patients. MSC’s therapeutic effect is displayed in their ability to reduce the cytokine storm, enhance alveolar fluid clearance, and promote epithelial and endothelial recovery; however, the safest and most effective route of MSC delivery remains unclear. The use of poorly characterized MSC products remains one of the most significant drawbacks of MSC-based therapy, which could theoretically promote the risk for thromboembolism. Optimizing the clinical-grade production of MSCs and establishing a consensus on registered clinical trials based on cell-product characterization and mode of delivery would aid in laying the foundation for a safe and effective therapy in COVID-19. In this review, we shed light on the mechanistic view of MSC therapeutic role based on preclinical and clinical studies on acute lung injury and ARDS; therefore, offering a unique correlation and applicability in COVID-19 patients. We further highlight the challenges and opportunities in the use of MSC-based therapy.</p><h2>Other Information</h2><p dir="ltr">Published in: Stem Cell Research & Therapy<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1186/s13287-020-01963-6" target="_blank">https://dx.doi.org/10.1186/s13287-020-01963-6</a></p>2020-10-15T12:00:00ZTextJournal contributioninfo:eu-repo/semantics/publishedVersiontextcontribution to journal10.1186/s13287-020-01963-6https://figshare.com/articles/journal_contribution/Potential_application_of_mesenchymal_stem_cells_and_their_exosomes_in_lung_injury_an_emerging_therapeutic_option_for_COVID-19_patients/26299555CC BY 4.0info:eu-repo/semantics/openAccessoai:figshare.com:article/262995552020-10-15T12:00:00Z |
| spellingShingle | Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients Sara Al-Khawaga (4792761) Biomedical and clinical sciences Cardiovascular medicine and haematology Medical biotechnology Stem cells MSCs SARS-CoV-2 ARDS Exosome Treatment Clinical trials Pneumonia |
| status_str | publishedVersion |
| title | Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients |
| title_full | Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients |
| title_fullStr | Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients |
| title_full_unstemmed | Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients |
| title_short | Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients |
| title_sort | Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients |
| topic | Biomedical and clinical sciences Cardiovascular medicine and haematology Medical biotechnology Stem cells MSCs SARS-CoV-2 ARDS Exosome Treatment Clinical trials Pneumonia |